TWTao Wang

Tao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tao Wang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Cory Heilmann

    Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA

    1 shared publication
  • Haoda Fu

    Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA

    1 shared publication
  • James Malone

    Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA

    1 shared publication
  • William J. Huster

    Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA

    1 shared publication
  • Yongming Qu

    Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA

    1 shared publication

Latest Publications

  • Open Access

    Crossover design and its application in late‐phase diabetes studies

    by Tao Wang, James Malone, Haoda Fu, Cory Heilmann, Yongming Qu, William J. Huster

    Crossover design has been widely used in late‐phase clinical studies, as well as in pharmacokinetic and pharmacodynamic, bioequivalence, and medical device studies; however, its interpretability and applicability continue to be debated. Herein we provide discussions around a crossover design's scientific benefit, applicability, and how it can be implemented in late‐phase diabetes studies by properly handling key issues: carryover effect, washout period, and baseline selection. Specifically, detailed considerations are provided about the validity and situations of having appropriate length of study duration to deal with carryover effects so that a washout period may not be needed. A simulation study and data mining results on 12 crossover late‐phase insulin clinical trials are presented to examine the discussion points and proposals.